<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20190611043861N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2019-07-02</date_registration>
      <primary_sponsor>Kerman University of Medical Sciences</primary_sponsor>
      <public_title>Comparison of Superficial Cervical Plexus Block Methods on the Severity of Pain After Thyroidectomy</public_title>
      <acronym></acronym>
      <scientific_title>Comparison of the Effectiveness of Superficial Cervical Plexus Block (SCPB) under Ultrasound-Guided  and via Landmark-Based on Severity of Pain After Thyroidectomy</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2019-06-22</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>102</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/40150</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Triple blinded, Placebo: Not used, Assignment: Parallel, Purpose: Supportive, Randomization description: In this study, simple randomization method using "Random Allocation software" will be used. The sample size (102 people) and the number of groups (3 groups) are included in the software. Then, based on the software output, the patients after going to the hospital will be allocated in one of the three groups: block under Ultrasound-guided, via Landmark and control, Blinding description: The patient is not aware of the grouping.
After surgery, the pain assessor is not aware of the grouping.
Data analyzer is not aware of the grouping.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Thyroidectomy, Superficial Cervical Plexus Block.</hc_freetext>
      <i_freetext>Intervention 1: First Intervention group: With the patient in supine position, the head turned slightly away from the side to be blocked. After prep the transducer is placed on the lateral neck, overlying the sternocleidomastoid muscle (SCM) at the level of its midpoint (approximately the level of the cricoid cartilage). Once the SCM is identified, the transducer is moved posteriorly until the tapering posterior edge is positioned in the middle of the screen. At this point, an attempt should be made to identify the brachial plexus and/or the interscalene groove between the anterior and middle scalene muscles. The plexus is visible as a small collection of hypoechoic nodules (honeycomb appearance) immediately underneath the prevertebral fascia that overlies the interscalene groove. Once identified, the needle is passed through the skin, platysma and prevertebral fascia, and the tip placed adjacent to the plexus. Following negative aspiration, 1 to 2 milliliter of Bupivacaine 0.25% is injected to confirm the proper injection site. Then the remainder of the local anesthetic (15 milliliters) is administered. Intervention 2: Second Intervention group: With the patient in supine position and the head turned slightly away from the side to be blocked,  is asked to lift his or her head off of the bed to accentuate the sternocleidomastoid muscle. The needle insertion site is along the posterior border of the sternocleidomastoid. After prep three injections of 5 milliliters of Bupivacaine 0.25% are injected behind the posterior border of the sternocleidomastoid muscle subcutaneously, perpendicularly, cephalad, and caudad in a fan fashion.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
All of the data can be shared after unidentifiable people.

When:
Start the access period 6 months after publishing the results

To whom:
Only for researchers working in academic and scientific institutions

Conditions:
Any analysis of the data is allowed but not published.
A written request with a valid letter from a University or scientific institution with an identification card is required.

Where to obtain:
Sadra Samadi

How to obtain:
A written request will be submitted to the research Vice-chancellor of the Kerman University of Medical Sciences with a valid letter from the University or institute.

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Sadra Samadi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>No. 1, Sarjangaldari Phase 1, Jomhouri Eslami Blvd</address>
        <city>Kerman</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>7618747319</zip>
        <telephone>+98 34 3211 4007</telephone>
        <email>s.samadi@kmu.ac.ir</email>
        <affiliation>Kerman University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Morteza Hashemian</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Shafa crossroad, Jomhouri Eslami Blvd</address>
        <city>Kerman</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>7616913555</zip>
        <telephone>+98 34 3211 3012</telephone>
        <email>mortezahashemian@kmu.ac.ir</email>
        <affiliation>Kerman University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>All Patients Candidates for Thyroidectomy Referred to Shahid Bahonar Hospital in Kerman, 2019</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>65 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Age under 18 years
Age over 65 years
History of previous thyroid or parathyroid and neck surgery
Retrosternal Goiter
Thyroid dysfunction
Urgent surgery within the first 24 hours
Body Mass Index More Than 25
Coagulation Abnormalities
Allergy to Bupivacain
ASA Class above 2
Short Neck
Pathology of Incision Site
Patient Refusal
Opioid Addiction</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>D34</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Benign neoplasm of thyroid gland</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Rehabilitation</i_code>
      <i_code>Rehabilitation</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>First Intervention group: With the patient in supine position, the head turned slightly away from the side to be blocked. After prep the transducer is placed on the lateral neck, overlying the sternocleidomastoid muscle (SCM) at the level of its midpoint (approximately the level of the cricoid cartilage). Once the SCM is identified, the transducer is moved posteriorly until the tapering posterior edge is positioned in the middle of the screen. At this point, an attempt should be made to identify the brachial plexus and/or the interscalene groove between the anterior and middle scalene muscles. The plexus is visible as a small collection of hypoechoic nodules (honeycomb appearance) immediately underneath the prevertebral fascia that overlies the interscalene groove. Once identified, the needle is passed through the skin, platysma and prevertebral fascia, and the tip placed adjacent to the plexus. Following negative aspiration, 1 to 2 milliliter of Bupivacaine 0.25% is injected to confirm the proper injection site. Then the remainder of the local anesthetic (15 milliliters) is administered.</i_keyword>
      <i_keyword>Second Intervention group: With the patient in supine position and the head turned slightly away from the side to be blocked,  is asked to lift his or her head off of the bed to accentuate the sternocleidomastoid muscle. The needle insertion site is along the posterior border of the sternocleidomastoid. After prep three injections of 5 milliliters of Bupivacaine 0.25% are injected behind the posterior border of the sternocleidomastoid muscle subcutaneously, perpendicularly, cephalad, and caudad in a fan fashion.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Pain Score Based on Visual Analog Scale. Timepoint: Pain Severity Evaluation, Immediately Post Operation and 3, 6, 9, 12 and 24 Hours After Surgery. Method of measurement: Visual Analogue Scale.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Total Postoperative Prescribed Opioid. Timepoint: First 24 Hours Post Operation. Method of measurement: Nursery Records.</sec_outcome>
      <sec_outcome>Total prescribed opioids during surgery. Timepoint: From beginning of surgery until the completion. Method of measurement: Anesthesia records.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Kerman University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2019-05-25</approval_date>
        <contact_name>Ethics committee of Kerman University of Medical Sciences</contact_name>
        <contact_address>Someyah crossroad, Beginning of Jahad Blvd, Beginning of Ibn Sina Street, In Front of Besat Clinic Kerman Kerman Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
